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of the EQ-5D-5L in HIV/AIDS patients
Bach Xuan Tran1,2*, Arto Ohinmaa1† and Long Thanh Nguyen3†Abstract
Objectives: We assessed health-related quality of life (HRQOL), its associated factors, and examined measurement
properties of the EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) in HIV/AIDS patients.
Methods: A cross-sectional multi-site survey was conducted in 1016 patients (age: 35.4 ± 7.0 years; 63.8% male) in
three epicenters of Vietnam. Internal consistency reliability, convergent validity, and discriminative validity of the
EQ-5D-5L and a visual analogue scale (VAS) were evaluated. Tobit censored regression models were used to identify
predictors of HRQOL in HIV/AIDS patients.
Results: The mean EQ-5D-5L single index and VAS were 0.65 (95% Confidence Interval (CI) = 0.63; 0.67) and
70.3 (95% CI = 69.2; 71.5). Cronbach’s alpha of five dimensions was 0.85. EQ-5D-5L has a good convergent validity
with VAS (0.73). It discriminated patients at different HIV/AIDS stages, duration of ART, and CD4 cell count.
Predictors of poorer HRQOL included being female, lower education level, unemployment, alcohol and drug use,
CD4<200 cells/mL, and advanced HIV/AIDS stages.
Conclusion: The EQ-5D-5L has good measurement properties in HIV/AIDS patients and holds potentials for
monitoring ART outcomes. Integration of HRQOL measurement using EQ-5D-5L in HIV/AIDS clinical practice could
be helpful for economic evaluation of HIV/AIDS interventions.
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Health-related quality of life (HRQOL) has become an
important indicator to assess outcomes of health inter-
ventions, as well as inform patient management and
policy development. In HIV research, HRQOL measure-
ment has advanced rapidly in recent years, especially
since antiretroviral treatment (ART) services were scaled-
up that transformed HIV/AIDS into a chronic illness [1].
Assessments of HRQOL supplements traditional mea-
sures of HIV-related morbidity and mortality. HRQOL
was found to be associated with physical and clinical
characteristics of HIV/AIDS patients, including oppor-
tunistic infections, immune status and viral load [2-4].
Moreover, HRQOL includes broader non-medical aspects
of patients living with HIV/AIDS, such as psychological,* Correspondence: bach@hmu.edu.vn
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reproduction in any medium, provided the orinterpersonal, spirituality, and environment [5,6]. There-
fore, measurements of HRQOL can better reflect
changes in HIV/AIDS patients and inform economic
evaluation of HIV/AIDS treatment services.
Basically, HRQOL can be assessed using generic or
condition specific measures. Generic measure included
health status profile or utility (preference-based) mea-
sures that provide a summary of HRQOL. Specific mea-
sures are those instruments which focus on problems
associated with single disease states, patient groups, or
areas of function [7]. There have been a number of
instruments, both generic or HIV/AIDS specific, applied
in HIV/AIDS patients, for instance, the WHOQOL-HIV,
MOS-HIV, EQ-5D, SF-6D [8-11]. While specific mea-
sures are sensitive to clinical aspects of HIV/AIDS, they
are often in the form of long profiles that might be time-
consuming and inconvenient in clinical practice. Generic
preference-based measures such as EQ-5D, SF-6D, in
contrast, come in a short and convenient form, thus,
would be easier to administer in HRQOL measurementsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a high ceiling effect and might be less responsive to
monitor changes in HRQOL of patients during ART
[12]. Recently, the EuroQOL Group has introduced a
5-level version of the EQ-5D. This promises better
measurement properties in terms of improving the
instrument’s sensitivity and reducing ceiling effects by
increasing the number of severity levels [13,14]. How-
ever, since this version is newly introduced, evidence
of its improvements in psychometric properties is very
limited.
Vietnam has one of the fastest growing HIV epidemics
in Asia, which was largely driven by high-risk behaviors,
including unsafe sex and drug injection [15,16]. Compre-
hensive HIV/AIDS care and treatment is a cost-effective
intervention recognized in the National HIV/AIDS Stra-
tegic Plan [16,17]. Over the last five years, ART services
have been rapidly scaled-up, covering 59,000 HIV/AIDS
patients, approximately 18 times the ART coverage in
2005. There have been 318 ART clinics established in
the country, of those 50% at the district, 48% at the pro-
vincial, and 2% at the central level [18]. The expansion
and decentralization of ART services promise substantial
benefits to HIV/AIDS patients and society. However, at
the same time, concerns are raised about the service’s
quality [19]. This underscores the importance of moni-
toring HIV/AIDS treatment outcomes as well as identify-
ing feasible and valid methods of HRQOL assessments.
In the present study, we assessed health-related quality
of life (HRQOL), its associated factors, and examined
measurement properties of the EuroQol - 5 Dimensions -
5 Levels (EQ-5D-5L) in HIV/AIDS patients attending
ART clinics in Vietnam.
Methods
Study design and participant recruitment
A cross-sectional study was conducted in Hanoi, Hai
Phong, and Ho Chi Minh City in 2012. These metropoli-
tans represent different geographical areas with the
largest HIV epidemics in Vietnam. Ha Noi is the capital
of Vietnam with a population of 6 million, among those,
18,108 people living with HIV. Hai Phong is a port city
in northern Vietnam of about 1.8 million citizens, among
those, 6930 HIV-positive cases reported. Ho Chi Minh
City is the biggest southern metropolitan centre, which
has the largest HIV-positive population nationwide with
46,507 cases over 8 million residents [20,21]. Seven
hospitals across levels of the health system were pur-
posively selected for the study where 1016 patients were
interviewed (17% of the total sample frame). The sample
size was allocated 20% for central (the National Hospital
for Tropical Diseases), 40% for provincial (Dong Da,
Viet Tiep, and Ho Chi Minh City Tropical Diseases
Hospitals), and 40% for district clinics (Tu Liem, LeChan, and Binh Tan district health center). The eligibility
criteria for ART in Vietnam during the period of this
study included a CD4 count less than 250 cells/mL.
Patients with HIV/AIDS, registering for care or treat-
ment at selected sites, and present at the clinics during
the period of the survey, were invited to participate in
the study. This included both inpatients and outpatients,
who came for receiving regular check-ups and ARV med-
ications. Selection of patients was basically convenient
until we got a sufficient sample size given the fact that
we could not develop a sample frame of HIV/AIDS
patients due to confidentiality. The response rate was
85-90% in different clinics.
Measures and instrument
Face-to-face interviews using a structured questionnaire
were carried out by well-trained health workers to collect
information about patient’s socioeconomic, HIV-related
characteristics, and HRQOL. The socioeconomic charac-
teristics included age, gender, marital status, education
level, employment, and income. Household’s monthly
income was self-reported by summing up all sources of
income from each member in 2011; and then stratified
into five quintiles. Health behaviors of interest, includ-
ing drug use, alcohol use, and adherence to ART, were
also self-reported by patients during the interview. We
used the Alcohol Use Disorders Identification Test -
Consumption (AUDIT-C) to assess alcohol use disorders
(AUD) in HIV/AIDS patients [22]. It includes three
questions: 1) How often do you have a dink containing
alcohol?; 2) How many standard drinks containing
alcohol do you have on a typical day?; and 3) How often
do you have six or more drinks on one occasion?
Responses to each question were assigned a score from
0 to 4 that make the AUDIT-C’s total score falls into a
scale of 0–12. Higher scores indicate higher likelihood
that the patient’s health and safety are at risk. An
AUDIT-C score of (4 or more) in men and (3 or more) in
women is considered positive and used for classifying
individuals with active AUD. The Vietnamese version of
AUDIT instrument was developed and validated [22,23].
Patients were asked if they had ever used opiates. In
a longitudinal study of drug users in Vietnam, self-
reported drug use was associated with changes in HRQOL
[24]. Patients’ adherence to ART over the last 30 days
was self-reported on a visual analogue scale (VAS). The
threshold for optimal adherence was defined at 95% and
above [25]. Clinical characteristic, including HIV/AIDS
stages, CD4 cell count, and the duration of ART were
extracted from medical records over the past three
months.
The EuroQOL - 5 Dimensions (EQ-5D) was employed
for measuring health-related quality of life of HIV/AIDS
patients. It consisted of a weighted sum of five dimensions:
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and Anxiety/Depression, which provided a simple de-
scriptive profile and a single index value for health status
[26]. The Vietnamese version of the EQ-5D 3-levels
has been applied in HIV/AIDS patients as well as general
population in Vietnam [27]. We used a recently devel-
oped version, the EQ-5D-5L, which includes five-level
response options: no problems, slight problems, moder-
ate problems, severe problems, and extreme problems
[14]. EQ-5D-5L defined 3125 health states, which were
converted into a single index. The Vietnamese version of
the EQ-5D was provided by the EuroQOL and culturally
adopted in Vietnam [27]. Prior to the survey, three focus
group discussions were carried out in researchers, inter-
viewers and HIV/AIDS patients to examine the relevance
of five new response options of the EQ-5D-5L. Since
population reference of Vietnam was not available, we
used the interim scoring for EQ-5D-5L from the cross-
walk value set of Thailand [28]. Besides, the EQ-5D-5L
also includes a visual analogue scale (EQ-VAS), which
recorded the patient’s self-rated health on a 20 cm verti-
cal, visual analogue scale with endpoints (0; 100) labeled
‘the best health you can imagine’ and ‘the worst health
you can imagine’. Finally, patients also reported their
general HRQOL on a global rating scale of five response
options: very poor, poor, moderate, good, and very good.Statistical analysis
Descriptive statistical analysis was used to describe the
socio-demographics and HIV-related characteristics, and
EQ-5D-5L health profile of respondents. ANOVA test
was used to examine the differences between means of
HRQOL of various patient groups.
Psychometric properties of the EQ-5D-5L measurement:
Internal consistency reliability of measurement was esti-
mated using Cronbach’s alpha. Although EQ-5D consists
of multiple dimensions with single items, the use of
Cronbach’s alpha for evaluating its reliability has been
reported in previous studies [29-32]. Discriminative
validity was assessed by testing “a priori” hypotheses
that the measure could distinguish patients who were
at different clinical groups: (1) HIV/AIDS stages, (2)
CD4 cell counts, and (3) Duration of ART; and who
had different health behaviors: (4) drug use and (5) alco-
hol use; and (6) who had suboptimal ART adherence
[18,24,27,33-36]. The differences between known groups
relative to standard deviation of EQ-5D index and VAS
score were estimated for assessing the effect size. Effect
size of (0.2-0.5), (0.5-0.8), and (>0.8) indicates small,
moderate and large differences in HRQOL. The percent-
age of respondents at floor and ceiling scores were exam-
ined for each dimension of the EQ-5D. The EQ-5D-5L
single index was correlated with VAS score and a globalrating of health-related quality of life to examine the
convergent validity of the measurement.
Multivariable linear regression was used to determine
factors associated with HRQOL domain’s scores. Since
the range of EQ-5D-5L single index and VAS ranged at
(−0.452; 1) and (0; 100), these scales were left- and right
censored. Censoring from above and below the HRQOL
scores did not allow us to measure exactly the values
which were higher or lower than the range thresholds.
Therefore, in regression analysis, we employed censored
regression models (Tobit models) to determined factors
associated with EQ-5D-5L single index and VAS [37].
Candidates for multivariate models included those
variables that met one of the following three criteria:
(1) socio-economic status, (2) biological association with
the outcome of interest; and (3) previously shown to be
associated with the health-related quality of life among
Vietnamese population [18,27,33]. We identified a set
of candidate variables, including: (1) patient’s character-
istics: gender, age, education, marital status, employment
and income; (2) HIV/AIDS-related characteristics: CD4
cell count, HIV stages, and ART; and (3) patient’s adher-
ence to ART, alcohol use, and drug use [18,24,27,33,38].
This set of candidate variables were entered in the full
regression models. After that, we applied a stepwise
forward selection to determine the reduced model
that selected variables based on the log-likelihood
ratio test at a p-value < 0.1, and excluded variables at
p-values >0.2.
Ethical consideration
The use of survey data was approved by the Authority
of HIV/AIDS Control, Ministry of Health of Vietnam.
Ethical approvals granted by the University of Alberta’s
Health Research Ethics Board. Written informed consent
was obtained from all participants after clearly introduce
the survey. Respondents could refuse to participate or
withdraw from the interview at any time, and this did
not affect their continuation of health care services.
Confidentiality was assured using codes of patient’s
information, and secured storage was prepared for both
paper questionnaires and electronic data set.
Results
Socio-demographic and clinical characteristics of
respondents
Of 1016 patients interviewed, 63.8% were male, average
age was 35.4 (SD=7.0), 45% had high school education
and above, and 20.4% had stable jobs. The average
monthly income per capita of their households was
roughly US$ 100 in 2011. As for HIV-related charac-
teristics, Table 1 shows that more than one-third of
respondents were in AIDS stage (37.6%), half of them
were symptomatic HIV stage (50%) and only 12.4% were
Table 1 EQ-5D-5L profile of patients by different disease stages
Asymptomatic Symptomatic AIDS All
N % N % N % N %
MOBILITY
- Unable to walk about 2 1.6 10 2.0 21 5.5 33 3.3
- Severe problems 7 5.6 24 4.7 22 5.8 53 5.2
- Moderate problems 9 7.1 49 9.7 34 8.9 92 9.1
- Slight problems 26 20.6 149 29.3 105 27.5 280 27.6
- No problems 82 65.1 276 54.3 200 52.4 558 54.9
SELF-CARE
- Unable to wash or dress myself 1 0.8 3 0.6 17 4.5 21 2.1
- Severe problems 15 3.0 11 2.9 26 2.6
- Moderate problems 1 0.8 22 4.3 18 4.7 41 4.0
- Slight problems 11 8.7 60 11.8 46 12.0 117 11.5
- No problems 113 89.7 408 80.3 290 75.9 811 79.8
USUAL ACTIVITIES
- Unable to do 2 1.6 8 1.6 24 6.3 34 3.4
- Severe problems 3 2.4 17 3.4 20 5.2 40 3.9
- Moderate problems 5 4.0 37 7.3 23 6.0 65 6.4
- Slight problems 21 16.7 119 23.4 81 21.2 221 21.8
- No problems 95 75.4 327 64.4 234 61.3 656 64.6
PAIN/DISCOMFORT
- Extreme pain 2 1.6 5 1.0 17 4.5 24 2.4
- Severe pain 19 3.7 18 4.7 37 3.6
- Moderate pain 5 4.0 52 10.2 38 10.0 95 9.4
- Slight pain 48 38.1 241 47.4 146 38.2 435 42.8
- No pain 71 56.4 191 37.6 163 42.7 425 41.8
ANXIETY/DEPRESSION
- Extremely 5 4.0 19 3.7 22 5.8 46 4.5
- Severely 6 4.8 49 9.7 32 8.4 87 8.6
- Moderately 17 13.5 96 18.9 59 15.5 172 16.9
- Slightly 50 39.7 225 44.3 157 41.1 432 42.5
- Not anxious or depressed 48 38.1 119 23.4 112 29.3 279 27.5
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among those, 55.3% have been treated for more than two
years. The majority of patients remained low CD4 cell
counts, 86.4% had <= 500 cells/mL. A large proportion
of the sample were those patients who had a history of
drug use (46.1%), and who reported having AUD (30.1%),
and who reported suboptimal adherence to ART (24.7%).
Quality profile and psychometric properties of the
EQ-5D-5L in HIV/AIDS patients
Table 1 describes the HRQOL profile of HIV/AIDS
patients by different disease stages. We found a lower
proportion of having no problems across all 5 HRQOL
dimensions in patients at later disease stages compared
to asymptomatic patients. Overall, it was the highest in
“Self-care” (79.8%) and the lowest in “Anxiety/Depression”(27.5%). The EQ-5D-5L showed a small proportion of
respondents reported “very poor” status; the highest was
6.3% in “Usual activities”. There were 18.8% patients
reported having no problem in all five dimensions. The
mean EQ-5D index and VAS were 0.65 (SD= 0.27) and
70.3 (SD=19), respectively.
Table 2 shows the “known groups” validity of the
EQ-5D-5L, both single index and VAS score, in dis-
criminating patients at different HIV/AIDS stages, CD4
cell count groups, duration of ART, and having AUD.
Differences between the highest and lowest HRQOL of
these known groups ranged from 0.2 (AUDIT-positive)
to 0.6 (CD4 counts), indicating “small” to “moderate”
effect sizes. In addition, the VAS could distinguish
IDU and non-IDU patients at a level of significance
p=0.09; however, the effect size was trivial. The
Table 2 HRQOL of different patient groups and discriminative validity of the EQ-5D-5L
N % EQ-5D Index VAS
Mean 95% CI p-value Mean 95% CI p-value
All patients 1016 100.0 0.65 0.63 0.67 70.34 69.17 71.51
HIV Stages
- Asymptomatic 126 12.4 0.73 0.69 0.77 <0.01 76.67 74.14 79.20 <0.01
- Symptomatic 508 50.0 0.65 0.63 0.67 70.72 69.15 72.29
- AIDS 382 37.6 0.62 0.59 0.66 67.79 65.66 69.91
CD4
<=200 249 31.1 0.58 0.54 0.61 <0.01 64.47 61.80 67.14 <0.01
200<cd4<=350 249 31.1 0.66 0.62 0.69 71.62 69.43 73.81
350<cd4<=500 194 24.2 0.73 0.70 0.75 75.57 73.48 77.65
>500 109 13.6 0.69 0.65 0.74 76.22 73.20 79.24
Duration of ART
Not yet 114 11.2 0.64 0.59 0.69 <0.01 68.15 64.50 71.80 <0.01
<=1 yr 196 19.3 0.58 0.54 0.62 65.53 62.57 68.50
1; <=2 144 14.2 0.65 0.61 0.69 71.54 68.58 74.49
2; <=4 270 26.6 0.68 0.65 0.71 71.76 69.56 73.95
4; <=7 292 28.7 0.68 0.64 0.71 72.52 70.44 74.60
IDU
- No 548 53.9 0.66 0.63 0.68 0.48 71.29 69.72 72.85 0.09
- Yes 468 46.1 0.64 0.62 0.67 69.24 67.46 71.01
AUDIT-positive
- No 710 69.9 0.67 0.65 0.69 <0.01 71.73 70.40 73.07 <0.01
- Yes 306 30.1 0.60 0.57 0.63 67.12 64.78 69.47
Optimal ART adherence
- No 660 75.3 0.65 0.63 0.67 0.91 71.15 69.69 72.62 0.47
- Yes 217 24.7 0.65 0.62 0.69 70.09 67.73 72.44
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was good (0.73), and with the global rating of HRQOL
was fair (0.36). Cronbach’s alpha of five dimensions
was 0.85.
Factors associated with HRQOL in HIV/AIDS patients
The mean of EQ-5D-5L single index and VAS was 0.65
(95% Confidence Interval (CI) = 0.63; 0.67) and 70.3
(95% CI = 69.2; 71.5), respectively (Table 2). Table 3 pre-
sents associations between patient’s characteristics and
EQ-5D-5L single index and VAS scores in reduced
multivariate models. Patients at the provincial level
reported lower HRQOL than whom attending central
clinics. Socio-demographic characteristics of respon-
dents negatively correlated with EQ-5D-5L single index
and VAS score included female sex, lower education at-
tainment, and unemployment. Later stages of HIV/AIDS
infections and deterioration in immune function were
associated with poorer HRQOL. Over the course of
ART, VAS score was lower in the first year of ART com-
pared to those not-yet taking it; meanwhile, EQ-5D-5L
single index was stable and significantly increased afterthe 2nd year of treatment. Besides, health behaviors also
predicted HRQOL in HIV/AIDS patients. Drug users
reported lower VAS score than non-drug users. Patients
who had AUD reported lower score in both VAS and
EQ-5D-5L single index than others.Discussion
We assessed the HRQOL of HIV/AIDS patients attend-
ing ART clinics using the EQ-5D-5L profile, single index,
and VAS, and determined the association of socioeco-
nomic and clinical characteristics and HRQOL. The in-
strument showed an excellent reliability and good
discriminative validity. We found a high proportion in
Anxiety/Depression and Pain/Discomfort among HIV/
AIDS patients who were taking ART. The health utility
of patients was 0.65 and 0.70 for EQ-5D-5L single
index and VAS, respectively. Gender, education, and
employment were significantly associated with HRQOL.
Advanced HIV/AIDS patients, poor immune status,
having AUD and drug use, were associated with poorer
HRQOL.
Table 3 Determinants of HRQOL in HIV/AIDS patients using EQ-5D-5L and VAS
EQ-5D index (−0.452; 1) VAS (0; 100)
Coef. 95% CI Coef. 95% CI
Level of Health System (a Central)
- Provincial −0.11*** (−0.16; -0.66) −7.8*** (−10.5; -5.0)
Gender (a Male)
- Female −4.5*** (−7.5; -1.6)
Education (a Below high school)
- High school and above 0.06** (0.01; 0.10) 3.8*** (1.0; 6.5)
Marital status (a Single)
- Live with spouse/partner −2.0 (−4.9; 0.9)
Employment (a Unemployment)
- Free-lancer b 0.12*** (0.06; 0.19) 9.6*** (5.9; 13.4)
- Stable jobs 0.09** (0.02; 0.17) 9.1*** (4.7; 13.6)
- Others 0.13*** (0.04; 0.23) 11.3*** (5.8; 16.8)
Income quintiles (a Poorest)
- Richest 0.05 (−0.01; 0.11)
HIV/AIDS Stages (a Asymptomatic)
- Symptomatic −0.2*** (−0.3; -0.1) −7.1*** (−12.0; -2.2)
- AIDS −0.1*** (−0.2; -0.1) −8.1*** (−13.2; -3.0)
CD4 cell count (a Less than 200)
200<cd4<=350 0.06** (0.00; 0.12) 4.5** (1.0; 8.0)
350<cd4<=500 0.15*** (0.08; 0.22) 8.8*** (4.9; 12.7)
>500 0.07* (−0.01; 0.15) 8.4*** (3.7; 13.0)
Duration of ART (a Not yet)
<=1 yr −4.8*** (−8.5; -1.2)
1– <=2 yrs
2– <=4 yrs 0.07** (0.01; 0.14)
4– <=7 yrs 0.08** (0.01; 0.14)
History of drug use −3.9*** (−6.8; -1.1)
Having AUD −0.06** (−0.11; -0.01) −3.1** (−6.2; -0.1)
Constant 0.65*** (0.55; 0.76) 74.0*** (67.3; 80.8)
*** p<0.01, ** p<0.05, * p<0.1, a Reference group.
b Self-employed, non-salary basis.
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ties of the new version - EQ-5D-5L in HIV/AIDS patients.
It showed that the reliability was 0.85, which was close
to the threshold of 0.90, indicating the potential use of
EQ-5D-5L for measuring HRQOL at an individual level.
In the literature, applications of the EQ-5D-3L in HIV/
AIDS showed its convergent validity with the MOS-HIV,
and discriminative validity with AIDS-defining events,
disease severity (CD4, viral load, and HIV/AIDS stages)
[35,36,39]. We observed the same validity of the EQ-5D-
5L in discriminating patients at different CD4 groups,
and HIV/AIDS stages. In addition, we found that EQ-
5D-5L could distinguish patients at different clinically
meaningful duration of ART. Another important charac-
teristic of the EQ-5D-5L was that it had a smaller ceiling
effect and average HRQOL score of the HIV/AIDSpopulation than the previous 3-level version [27]. There-
fore, there will be room for assessing the improvements
of HRQOL overtime if one would like to use this tool for
longitudinal assessments. Consequently, findings of this
study contribute to the cumulative evidence of measure-
ment properties of the EQ-5D instruments in HIV/AIDS
population that may inform the selection of measures in
both cross-sectional and follow-up designs.
Compared with previous studies, we found some
similar influential factors of HRQOL in HIV/AIDS
patients, for example, employment was positively asso-
ciated with HRQOL [27,33]. As for the duration of ART,
there was a consistent finding that patients might experi-
ence HRQOL reduction during the ART compared to
those not-yet-eligible for ART [27]. This could be due to
the immune deterioration and negative impact of ART
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during ART were non-linear: it decreased within the first
year of ART, but then increased afterwards. We also con-
firmed the negative impacts of alcohol use and drug use
on HRQOL outcomes of ART for HIV/AIDS patients
[24,27]. In practice, both alcohol and drug use are known
to be associated with delayed access to health care, sub-
optimal adherence, more severe co-morbidities, and
poorer outcomes of ART [22,24].
This study has helpful implications for both HRQOL
assessments and ART services. The measurement prop-
erties of the EQ-5D-5L holds potentials in monitoring
changes in HRQOL, which are associated with meaningful
clinical indicators, such as, CD4 thresholds, HIV/AIDS
progression, or responses to ART treatment. Moreover,
it helps identify areas for interventions to improve the
health outcomes of patients. In this study, we observed a
very high prevalence of reported problems in Anxiety/
Depression that suggests the necessity of psychological
support during ART for HIV/AIDS patients. As for the
patient management, the 1st year ART is an important
period when we observed a significant reduction in
HRQOL. During this period, patients had to adapt with
the strict compliance, residual opportunistic infections,
and side effects of antiretroviral medications. The adher-
ence should also be maintained during more stable peri-
ods of ART afterwards. In the Vietnamese settings,
stigma and discrimination were found to be a significant
barrier that affected adherence to and HRQOL outcomes
of ART [27]. The reduction in HRQOL observed in
women suggests that gender-specific impact mitigation
and support interventions should be in place. Previous
works identified that peer’s support, vocational training,
job referrals, and microfinance are potential interven-
tions to support women with HIV/AIDS [27,33,40-42].
The strengths of this study include the involvement
of patients in three epicenters across levels of health
systems and geographical areas of Vietnam. In addition,
we employed the Thailand tariff for deriving the EQ-
5D-5L index, which has close culture and other charac-
teristics with Vietnam. Besides, there were some limita-
tions that should be acknowledged. First, we did not have
viral load assessments, a gold standard in monitoring
ART outcomes, since viral load tests are costly and not
regularly assessed for all HIV/AIDS patients in Vietnam.
Second, tests of convergent validity compared only the
measures derived from the same EQ-5D instrument.
Moreover, the cross-sectional design might be less cap-
able for causal inference as well as for assessing the re-
sponsiveness of the EQ-5D-5L in this measurement. In
addition, patients at clinics were selected conveniently
making the sample not representative for the popula-
tion of HIV/AIDS patients and limiting the
generalizability of study findings.In conclusion, the EQ-5D-5L showed good properties
in measuring HRQOL of HIV/AIDS patients and has
potentials for monitoring ART outcomes. Integration of
HRQOL measurement using EQ-5D-5L in HIV/AIDS
clinical practice could be helpful for economic evalu-
ation of HIV/AIDS interventions. Further research to
develop a scoring system of the Vietnamese population
is recommended.
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